Sanofi (NASDAQ:SNY) Shares Acquired by Keystone Financial Services

Keystone Financial Services increased its position in Sanofi (NASDAQ:SNY) by 7.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,605 shares of the company’s stock after acquiring an additional 892 shares during the period. Keystone Financial Services’ holdings in Sanofi were worth $784,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Addison Advisors LLC increased its holdings in shares of Sanofi by 22.1% in the 3rd quarter. Addison Advisors LLC now owns 1,311 shares of the company’s stock worth $76,000 after acquiring an additional 237 shares during the period. Catalytic Wealth RIA LLC boosted its holdings in shares of Sanofi by 37.5% in the third quarter. Catalytic Wealth RIA LLC now owns 12,853 shares of the company’s stock valued at $741,000 after acquiring an additional 3,503 shares in the last quarter. Crossmark Global Holdings Inc. increased its stake in shares of Sanofi by 23.7% during the third quarter. Crossmark Global Holdings Inc. now owns 44,289 shares of the company’s stock valued at $2,552,000 after acquiring an additional 8,494 shares during the period. Axxcess Wealth Management LLC raised its holdings in Sanofi by 75.2% during the third quarter. Axxcess Wealth Management LLC now owns 8,153 shares of the company’s stock worth $470,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Legacy Capital Wealth Partners LLC lifted its position in Sanofi by 114.2% in the third quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock worth $1,399,000 after purchasing an additional 12,942 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Trading Down 1.4 %

NASDAQ:SNY opened at $50.62 on Tuesday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 1-year low of $45.13 and a 1-year high of $58.97. The firm has a market capitalization of $128.46 billion, a price-to-earnings ratio of 25.83, a price-to-earnings-growth ratio of 1.31 and a beta of 0.61. The stock has a fifty day simple moving average of $55.38 and a 200 day simple moving average of $52.24.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same quarter last year, the company posted $2.55 EPS. Sanofi’s revenue for the quarter was up 12.3% on a year-over-year basis. Sell-side analysts forecast that Sanofi will post 4.27 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on SNY shares. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Argus boosted their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.